Research into individual predisposition to develop acute rhabdomyolysis attributed to fenoverine

Human & Experimental Toxicology

Volumn 15, Issue 10, 1996, Pages 815-820

  Jouglard, Jacqueline ^a   Kozak Ribbens, Geneviève ^b   de Haro, Luc ^a   Cozzone, Patrick J ^b  

^a Centre Antipoisons de Marseille   (France)

^b University of Aix Marseille   (France)

Author keywords

fenoverine; genetic predisposition; malignant hyperthermia; muscle oxidative dysfunction; rhabdomyolysis

Indexed keywords

FENOVERINE; PHENOTHIAZINE; XENOBIOTIC AGENT;

ADULT; AEROBIC METABOLISM; AGED; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; DRUG MONITORING; DRUG SENSITIVITY; DRUG STRUCTURE; FEMALE; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; LIPIDOSIS; MALE; MALIGNANT HYPERTHERMIA; METABOLIC DISORDER; MITOCHONDRIAL MYOPATHY; MUSCLE CONTRACTION; MYALGIA; MYOPATHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PRIORITY JOURNAL; RHABDOMYOLYSIS;

BIOPSY; CARNITINE O-PALMITOYLTRANSFERASE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MUSCLE CONTRACTION; MUSCLE, SKELETAL; PARASYMPATHOLYTICS; PHENOTHIAZINES; PHOSPHORUS ISOTOPES; RHABDOMYOLYSIS;

EID: 0029805475     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/096032719601501004     Document Type: Article

References (15)

1. Swiss Pharmaceutical Society, INDEX NOMINUM International Drug Directory. Bern: Medpharm Scientific Publishers, 1990.
2. Chichmanian RM, Fuzibet JG, Mignot G., Dujardin P. Rhabdomyolyses aigues dues à la Fénovérine. Annales de médecine interne 1990; 141: 490-1.
3. Chichmanian RM et al. Rhabdomyolyses dues à la Fénovérine: analyse de 45 cas. Bulletin de la société nationale francaise de médecine interne 1992; 14(27): 114.
4. Kozak-Ribbens G. Investigation and diagnosis of malignant and exercise hyperthermias. In: Aubert M, Borsarelli J, Kozak-Ribbens G. Malignant Hyperthermias. Madrid: Normed Verlag, 1993.
5. Begaud B., Evreux JC, Jouglard J., Lagier G. Unexpected or toxic drug reaction assessment (imputation). Actualization of the method used in France. Thérapie 1985; 40: 115-8.
6. Perrot D., Motin J. Rhabdomyolyse traumatiques et non traumatiques. Encyclopédie médicochirurgicale- Anesthésie-réanimation (Paris) 1985; 36 918 A10: 10p.
7. Bendahan D., Confort-Gouny S., Kozak-Ribbens G., Cozzone PJ Investigation of metabolic myopathies by P31 MRS using a standardized rest-exercise-recovery protocol: a survey of 800 explorations. Magma 1993; 1: 91-104.
8. Bendahan D. et al. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology 1992; 4: 1203-8.
9. Heytens L., Martin JJ, Van de Kelft E., Bossaert LL In vitro contracture tests patients with various neuromuscular diseases. British Journal of Anaesthesia 1992; 68: 72-5.
10. Kozak-Reiss G., Borsarelli J. A rapid and extensive investigation of MH patients in Marseille by a pluridisciplinary integrated structure. Journal of Neurological Sciences 1990; 985: 518.
11. Kozak-Reiss G., Coursange F., Aubert M. Hyperthermies malignes. Encyclopédie médicochirurgicale- Techniques chirurgicales, Anesthésie-réanimation (Paris) 1991; 364 12E10: 17p.
12. The European Malignant Hyperpyrexia Group et al. A protocol for investigation of malignant hyperpyrexia susceptibility. British Journal of Anaesthesia 1984; 56: 1267.
13. Kozak-Ribbens G. Malignant hyperthermia, heat stroke and mitochondrial myopathies. VI th International Malignant Hyperthermia Workshop, Hershey (Pennsylvania), 16-20 Sept. 1992.
14. Rodet L. Incidence élevée de tests de contracture halothane-caféine posotifs chez 13 patients souffrant de rhabdomyolyse d'effort. 5ème Colloque national sur les maladies neuromusculaires, Strabourg (France), 21-25 June 1993.
15. Sporn P. Maligne Hyperthermia. Wiener Klinische Wochenschrift 1993; 23 (5132): 3-28.